ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.693,37
0,04%
S&P 500
5.304,72
0,70%
Dow Jones
39.069,59
0,01%
Euro vs US Dollar
1,08445
0,30%
Bitcoin
68.853,14
1,37%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Eledon Pharmaceuticals Inc (ELDN)

  7. Eledon Pharmaceuticals Inc (ELDN) News

ELDN

Eledon Pharmaceuticals (ELDN)

Eledon Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ELDN
DatumZeitQuelleÜberschriftSymbolFirma
24/05/202422h02Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ELDNEledon Pharmaceuticals Inc
15/05/202413h00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ELDNEledon Pharmaceuticals Inc
13/05/202422h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELDNEledon Pharmaceuticals Inc
09/05/202413h30GlobeNewswire Inc.Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial ResultsNASDAQ:ELDNEledon Pharmaceuticals Inc
09/05/202413h00GlobeNewswire Inc.Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant CongressNASDAQ:ELDNEledon Pharmaceuticals Inc
07/05/202413h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELDNEledon Pharmaceuticals Inc
07/05/202413h05GlobeNewswire Inc.Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant RejectionNASDAQ:ELDNEledon Pharmaceuticals Inc
07/05/202413h00GlobeNewswire Inc.Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private PlacementNASDAQ:ELDNEledon Pharmaceuticals Inc
28/03/202421h01GlobeNewswire Inc.Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial ResultsNASDAQ:ELDNEledon Pharmaceuticals Inc
25/03/202421h56GlobeNewswire Inc.Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ RejectionNASDAQ:ELDNEledon Pharmaceuticals Inc
21/03/202415h31GlobeNewswire Inc.Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a HumanNASDAQ:ELDNEledon Pharmaceuticals Inc
14/02/202421h35Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ELDNEledon Pharmaceuticals Inc
14/02/202421h01Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ELDNEledon Pharmaceuticals Inc
14/02/202401h01GlobeNewswire Inc.Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ELDNEledon Pharmaceuticals Inc
04/01/202422h40GlobeNewswire Inc.Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 OutlookNASDAQ:ELDNEledon Pharmaceuticals Inc
05/12/202300h00GlobeNewswire Inc.Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ELDNEledon Pharmaceuticals Inc
29/11/202322h05GlobeNewswire Inc.Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity ConferenceNASDAQ:ELDNEledon Pharmaceuticals Inc
09/11/202323h00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ELDNEledon Pharmaceuticals Inc
09/11/202322h01GlobeNewswire Inc.Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial ResultsNASDAQ:ELDNEledon Pharmaceuticals Inc
08/11/202322h05GlobeNewswire Inc.Eledon Pharmaceuticals to Present at Jefferies London Healthcare ConferenceNASDAQ:ELDNEledon Pharmaceuticals Inc
02/11/202321h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELDNEledon Pharmaceuticals Inc
02/11/202314h05GlobeNewswire Inc.Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney TransplantationNASDAQ:ELDNEledon Pharmaceuticals Inc
23/10/202313h00GlobeNewswire Inc.Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical OfficerNASDAQ:ELDNEledon Pharmaceuticals Inc
13/10/202313h00GlobeNewswire Inc.Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual MeetingNASDAQ:ELDNEledon Pharmaceuticals Inc
03/10/202322h19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELDNEledon Pharmaceuticals Inc
03/10/202322h17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELDNEledon Pharmaceuticals Inc
02/10/202323h51Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ELDNEledon Pharmaceuticals Inc
02/10/202323h08Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ELDNEledon Pharmaceuticals Inc
02/10/202313h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELDNEledon Pharmaceuticals Inc
02/10/202313h00GlobeNewswire Inc.Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of DirectorsNASDAQ:ELDNEledon Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ELDN

Kürzlich von Ihnen besucht

USOTC
DTEGY
Deutsche Telekom (QX)
CCOM
US30
US 30
CCOM
US500
US 500
COIN
BTCUSD
Bitcoin
NASDAQ
AMZN
Amazon.com
DBI
SDXP
SDAX
NYSE
KO
Coca Cola
DBI
TDXP
Tec DAX
NASDAQ
MSFT
Microsoft
TG
BAS
BASF
NASDAQ
TSLA
Tesla
TG
NOV
Novo Nordisk
NASDAQ
AAPL
Apple
NYSE
MCD
McDonalds
FX
EURGBP
Euro vs Sterling
COIN
ETHUSD
Ethereum
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten